226 related articles for article (PubMed ID: 12921217)
1. Pharmacokinetics of pegfilgrastim.
Zamboni WC
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):9S-14S. PubMed ID: 12921217
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
3. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).
Molineux G
Curr Pharm Des; 2004; 10(11):1235-44. PubMed ID: 15078138
[TBL] [Abstract][Full Text] [Related]
4. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
5. Pegfilgrastim.
Curran MP; Goa KL
Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
[TBL] [Abstract][Full Text] [Related]
6. Pegfilgrastim.
Willis F; Pettengell R
Expert Opin Biol Ther; 2002 Dec; 2(8):985-92. PubMed ID: 12517276
[TBL] [Abstract][Full Text] [Related]
7. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.
Yang BB; Savin MA; Green M
Chemotherapy; 2012; 58(5):387-98. PubMed ID: 23296266
[TBL] [Abstract][Full Text] [Related]
8. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
9. Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.
Arvedson T; O'Kelly J; Yang BB
BioDrugs; 2015 Jun; 29(3):185-98. PubMed ID: 25998211
[TBL] [Abstract][Full Text] [Related]
10. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Crawford J
Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
[TBL] [Abstract][Full Text] [Related]
11. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model.
Kotto-Kome AC; Fox SE; Lu W; Yang BB; Christensen RD; Calhoun DA
Pharmacol Res; 2004 Jul; 50(1):55-8. PubMed ID: 15082029
[TBL] [Abstract][Full Text] [Related]
12. Novel effects with polyethylene glycol modified pharmaceuticals.
Yowell SL; Blackwell S
Cancer Treat Rev; 2002 Apr; 28 Suppl A():3-6. PubMed ID: 12173408
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
Crawford J
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
[TBL] [Abstract][Full Text] [Related]
14. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.
Lyman GH
Expert Opin Biol Ther; 2005 Dec; 5(12):1635-46. PubMed ID: 16318427
[TBL] [Abstract][Full Text] [Related]
15. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats.
Yang BB; Lum PK; Hayashi MM; Roskos LK
J Pharm Sci; 2004 May; 93(5):1367-73. PubMed ID: 15067712
[TBL] [Abstract][Full Text] [Related]
16. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.
Scholz M; Engel C; Apt D; Sankar SL; Goldstein E; Loeffler M
Cell Prolif; 2009 Dec; 42(6):823-37. PubMed ID: 19780759
[TBL] [Abstract][Full Text] [Related]
18. PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia.
Yoo N; Lee HR; Shin SH; Sohn KY; Kim HJ; Han YH; Chong S; Kim MH; Yoon SY; Kim JW
Cancer Lett; 2016 Jul; 377(1):25-31. PubMed ID: 27105612
[TBL] [Abstract][Full Text] [Related]
19. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
20. Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia.
Petros WP
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):1S-2S; quiz 20S-23S. PubMed ID: 12921215
[No Abstract] [Full Text] [Related]
[Next] [New Search]
